Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ionis Pharmaceutical (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 6,814,631
  • Shares Outstanding, K 123,970
  • Annual Sales, $ 346,620 K
  • Annual Income, $ -86,560 K
  • 36-Month Beta 3.20
  • Price/Sales 19.57
  • Price/Cash Flow 0.00
  • Price/Book 33.59

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.56 +24.04%
on 05/31/17
55.60 -0.59%
on 06/26/17
+8.89 (+19.17%)
since 05/26/17
3-Month
37.26 +48.34%
on 04/06/17
55.60 -0.59%
on 06/26/17
+16.29 (+41.79%)
since 03/24/17
52-Week
20.49 +169.74%
on 06/27/16
57.00 -3.04%
on 12/27/16
+33.30 (+151.57%)
since 06/24/16

Most Recent Stories

More News
Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the completion of enrollment in the Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in patients with Huntington's...

IONS : 55.31 (+0.62%)
Akcea Therapeutics Launches Proposed Initial Public Offering

Akcea Therapeutics, Inc. today announced that it has launched the proposed initial public offering of its common stock.

IONS : 55.31 (+0.62%)
Why is Alnylam's (ALNY) Stock Close to 100% this Year?

Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.

ALNY : 82.18 (-3.56%)
IONS : 55.31 (+0.62%)
NVS : 85.95 (-0.45%)
RHHBY : 32.4100 (-1.07%)
Technical Snapshots for These Drug Makers Stocks -- Endo, Teva Pharma, Ionis Pharma, and Amarin

Today, DailyStockTracker.com reviews Endo International PLC (NASDAQ: ENDP), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), and Amarin Corp. PLC (NASDAQ: AMRN)....

ENDP : 12.00 (+1.35%)
AMRN : 3.47 (+3.27%)
IONS : 55.31 (+0.62%)
TEVA : 32.99 (+1.17%)
Biogen/Ionis Spinraza Granted Marketing Authorization in EU

Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q...

BAYRY : 136.8000 (+0.32%)
VVUS : 1.21 (-0.82%)
IONS : 55.31 (+0.62%)
BIIB : 281.98 (+0.59%)
SPINRAZA® (nusinersen) Approved in the European Union

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the European Commission (EC) has granted marketing authorization for SPINRAZA® (nusinersen) for the treatment of 5q spinal muscular atrophy...

IONS : 55.31 (+0.62%)
SPINRAZA(R) (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy

--Robust Data From Phase 3 Studies Demonstrated Positive Impact on Motor Milestone Achievement; Increased Survival in Infants with SMA

IONS : 55.31 (+0.62%)
BIIB : 281.98 (+0.59%)
Biogen's Fampyra Conditional Approval Converted to Standard

Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard...

IONS : 55.31 (+0.62%)
ABBV : 72.58 (-0.08%)
ACOR : 19.30 (-0.77%)
BIIB : 281.98 (+0.59%)
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

Quite a few deals were announced this week including by companies like Biogen (BIIB).

SGMO : 9.50 (+2.15%)
AKBA : 16.31 (-0.24%)
VRTX : 132.85 (-0.49%)
IONS : 55.31 (+0.62%)
REGN : 513.21 (-0.80%)
ALXN : 125.77 (-0.24%)
BIIB : 281.98 (+0.59%)
Ionis (IONS) Stock Falls Despite Positive Inotersen Data

Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.

VVUS : 1.21 (-0.82%)
IONS : 55.31 (+0.62%)
MEIP : 2.27 (-1.30%)
GSK : 44.20 (-0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.

See More

Support & Resistance

2nd Resistance Point 56.04
1st Resistance Point 55.50
Last Price 55.31
1st Support Level 54.28
2nd Support Level 53.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.